Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women

被引:384
作者
Strickler, HD
Burk, RD
Fazzari, M
Anastos, K
Minkoff, H
Massad, LS
Hall, C
Bacon, M
Levine, AM
Watts, DH
Silverberg, MJ
Xue, XN
Schlecht, NF
Melnick, S
Palefsky, JM
机构
[1] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10461 USA
[2] Maimonides Hosp, Brooklyn, NY 11219 USA
[3] So Illinois Univ, Sch Med, Springfield, IL USA
[4] Georgetown Univ, Ctr Med, Washington, DC USA
[5] Univ So Calif, Los Angeles, CA USA
[6] NICHHD, Bethesda, MD 20892 USA
[7] Johns Hopkins Univ, Baltimore, MD USA
[8] NCI, Bethesda, MD 20892 USA
[9] Univ Calif San Francisco, San Francisco, CA 94143 USA
关键词
D O I
10.1093/jnci/dji073
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Little is known in human immunodeficiency virus (HIV)-positive women about how the combination of plasma HIV RNA level and CD4(+) T-cell count is associated with the natural history of human papillomavirus (HPV) infection or about HPV reactivation-whether it occurs and with what frequency in HIV-positive women. Methods: HIV-positive (n = 1848) and -negative (n = 514) women were assessed at semiannual visits (total person-years = 5661) for cervicovaginal HPV with polymerase chain reaction assays and for squamous intraepithelial lesions (SILs) by Pap smear. We studied the prevalent detection of HPV and SILs with generalized estimating equations and the incident detection and persistence of HPV and SILs with multivariable Cox models. All statistical tests were two-sided. Results: We observed a strong interaction between the associations of CD4+ and plasma HIV RNA strata with both prevalent (P-interaction =.002) and incident (P-interaction =.001) detection of HPV. Indeed, the hazard ratio for incident HPV detection peaked between 4.0 and 5.0, with either a CD4(+) count of less than 200 cells per mm(3) or an HIV RNA level of more than 100 000 copies per mL. Although incident HPV detection in all women was associated with the number of recent sex partners (P-trend <.001), 22% of sexually inactive HIV-positive women with a CD4(+) count of less than 200 cells/mm(3) also had at least one incidently detected HPV type. The association between CD4'/HIV RNA strata and HPV persistence was statistically significantly smaller (P <.001) than for incident HPV detection. SIL prevalence, incident detection, and persistence had similar associations with CD4(+)/HIV RNA strata as HPV (above). Conclusion: In HIV-positive women, plasma HIV RNA level and CD4(+) count in combination appear to have a strong and statistically interactive association with incident detection of HPV, some of which may reflect HPV reactivation (e.g., in sexually inactive women). The more moderate association between HIV coinfection and HPV persistence could partly explain why cervical cancer rates have not reached more epidemic proportions in HIV-positive women.
引用
收藏
页码:577 / 586
页数:10
相关论文
共 56 条
[1]  
Ahdieh L, 2000, AM J EPIDEMIOL, V151, P1148, DOI 10.1093/oxfordjournals.aje.a010165
[2]   Prevalence, incidence, and type-specific persistence of human papillomavirus in human immunodeficiency virus (HIV)-positive and HIV-negative women [J].
Ahdieh, L ;
Klein, RS ;
Burk, R ;
Cu-Uvin, S ;
Schuman, P ;
Duerr, A ;
Safaeian, M ;
Astemborski, J ;
Daniel, R ;
Shah, K .
JOURNAL OF INFECTIOUS DISEASES, 2001, 184 (06) :682-690
[3]   PRACTICAL PROBLEMS IN FITTING A PROPORTIONAL HAZARDS MODEL TO DATA WITH UPDATED MEASUREMENTS OF THE COVARIATES [J].
ALTMAN, DG ;
DESTAVOLA, BL .
STATISTICS IN MEDICINE, 1994, 13 (04) :301-341
[4]   The Women's Interagency HIV Study [J].
Barkan, SE ;
Melnick, SL ;
Preston-Martin, S ;
Weber, K ;
Kalish, LA ;
Miotti, P ;
Young, M ;
Greenblatt, R ;
Sacks, H ;
Feldman, J .
EPIDEMIOLOGY, 1998, 9 (02) :117-125
[5]   PREVALENCE OF HUMAN PAPILLOMAVIRUS IN CERVICAL-CANCER - A WORLDWIDE PERSPECTIVE [J].
BOSCH, FX ;
MANOS, MM ;
MUNOZ, N ;
SHERMAN, M ;
JANSEN, AM ;
PETO, J ;
SCHIFFMAN, MH ;
MORENO, V ;
KURMAN, R ;
SHAH, KV ;
ALIHONOU, E ;
BAYO, S ;
MOKHTAR, HC ;
CHICAREON, S ;
DAUDT, A ;
DELOSRIOS, E ;
GHADIRIAN, P ;
KITINYA, JN ;
KOULIBALY, M ;
NGELANGEL, C ;
TINTORE, LMP ;
RIOSDALENZ, JL ;
SARJADI ;
SCHNEIDER, A ;
TAFUR, L ;
TEYSSIE, AR ;
ROLON, PA ;
TORROELLA, M ;
TAPIA, AV ;
WABINGA, HR ;
ZATONSKI, W ;
SYLLA, B ;
VIZCAINO, P ;
MAGNIN, D ;
KALDOR, J ;
GREER, C ;
WHEELER, C .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (11) :796-802
[6]  
Brambilla AM, 2001, J ACQ IMMUN DEF SYND, V27, P44, DOI 10.1097/00126334-200105010-00008
[7]  
Broker T R, 2001, Dev Biol (Basel), V106, P443
[8]  
Broker TR, 2001, DEV BIOL BASEL, V106, P65
[9]  
Broker TR, 2001, DEV BIOL BASEL, V106, P52
[10]  
BUONAGURO FM, 1994, ANTIBIOT CHEMOTHER, V46, P102